Immune checkpoint inhibitor (ICI) therapies which target the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) or the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) alone or in combination are used in the treatment of multiple advanced solid tumours including metastatic melanoma. Here, PDCD1 is linked to metastatic melanoma.